📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-03 21:27
709 analysed today
709
Today
133,598
All-time analysed
40,124
Positive
6,284
Negative
79,370
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
23 announcements match the current filters (relevance ≥ 5).
Laxmi Dental seeks nod to reallocate ₹48.1 Cr unutilised IPO funds for new plant capex
Laxmi Dental has issued its 22nd AGM notice scheduled for September 25, 2026, seeking shareholder approval to vary the utilisation of IPO proceeds. Out of total IPO proceeds of ₹128.17 Cr (INR 1,281.70 Mn), ₹80.07 Cr (62.47%) has been utilised as of August 18, 2026. The company proposes to reallocate the remaining unutilised ₹48.10 Cr towards land acquisition and construction of a dental laboratory and aligner facility (₹26.90 Cr) and equipment/machinery (₹21.21 Cr). The revised deployment is slated across FY27 and FY28, requiring a 90% voting threshold to take effect.
Confidence: HIGH
What changedLaxmi Dental is redirecting ₹48.10 Cr of unutilised IPO proceeds from standalone machinery purchases towards acquiring land, building civil infrastructure, and equipping a new dental aligner and lab plant.
Why it mattersThe reallocation shifts capital deployment towards building an owned, integrated manufacturing facility by FY28, providing physical capacity to scale high-margin aligner and laboratory products.
Total IPO proceeds: INR 1,281.70 millionUtilised amount (62.47%): INR 800.67 millionReallocated capex amount: INR 481.03 millionLand and construction allocation: INR 268.96 millionMachinery & equipment allocation: INR 212.07 millionReallocated capex vs TTM revenue: ~16.8%
📅 Short termNear-term impact is administrative; attention remains on shareholder approval at the AGM on September 25, 2026.
📈 Long termSetting up an integrated manufacturing facility across FY27-FY28 supports the company's 20-25% structural revenue growth targets and aligner business scaling.
⚠ Risk flags
- Resolution requires a high approval threshold of >=90% of votes cast to be implemented
- Execution risks including land due diligence, regulatory approvals, and civil construction timelines
Key Highlights
AGM scheduled for September 25, 2026; seeks approval to vary IPO proceeds utilisation
₹80.07 Cr (62.47%) of ₹128.17 Cr IPO proceeds utilised as of August 18, 2026
₹48.10 Cr unutilised funds reallocated to land acquisition, construction (₹26.90 Cr), and equipment (₹21.21 Cr)
Capex deployment extended across FY27 and FY28 following LOI signed on July 30, 2026 for land acquisition
Special resolution requires approval by at least 90% of votes cast to be implemented
👀 What to Watch
Track the e-voting results post the September 25, 2026 AGM to confirm the 90% voting approval, followed by execution of definitive land acquisition agreements.
Laxmi Dental Proposes Variation in IPO Objects & Timeline; Allots 7,911 ESOP Shares
Laxmi Dental Limited's Board of Directors met on August 27, 2026, and approved a proposed variation in the objects of its IPO proceeds along with an extension of the timeline for utilization, subject to shareholder approval. The Board also approved the allotment of 7,911 equity shares of face value INR 2 each under the Laxmi Dental Stock Option Scheme 2024. Consequently, the company's paid-up equity share base expanded marginally from 5,50,21,509 to 5,50,29,420 shares. Detailed rationale and revised allocations regarding the IPO proceeds will be provided in the upcoming shareholder notice.
Confidence: HIGH
What changedThe Board approved the allotment of 7,911 ESOP shares and proposed modifying the objects and utilization schedule of its IPO proceeds.
Why it mattersChanges to IPO fund utilization timelines or objectives can alter planned project execution schedules and cash deployment efficiency.
ESOP shares allotted: 7,911Pre-allotment shares: 5,50,21,509Post-allotment shares: 5,50,29,420Face value per share: INR 2
📅 Short termMarket attention will shift to the detailed explanatory statement to see which projects face timeline extensions or budget reallocations.
📈 Long termDelays or shifts in capital expenditure funded by IPO proceeds could push back expected operational milestones and capacity timelines.
⚠ Risk flags
- Uncertainty around the redeployment or delayed deployment of IPO proceeds
- Minor equity dilution from ESOP allotment
Key Highlights
Allotted 7,911 equity shares of face value INR 2 under Laxmi Dental Stock Option Scheme 2024
Total paid-up share count increased from 5,50,21,509 to 5,50,29,420 equity shares
Approved proposed variation in IPO objects and extension of utilization timeline, subject to shareholder vote
👀 What to Watch
Review the upcoming shareholder notice and explanatory statement to assess the revised capital allocation schedule and reasons for altering IPO fund deployment.
Laxmi Dental reallocates ₹48.1 Cr unutilized IPO proceeds for new plant construction by FY28
Laxmi Dental's Board approved a variation in its IPO proceeds utilization, reallocating ₹48.10 Cr (INR 481.03 million) of unutilized funds toward land acquisition, facility construction, and equipment. Out of ₹128.17 Cr raised, the company has utilized ₹80.07 Cr (62.47%) as of August 18, 2026. The remaining funds are earmarked for a dental laboratory and aligner facility across FY27 and FY28, subject to shareholder approval. Additionally, 7,911 ESOP shares were allotted.
Confidence: HIGH
What changedLaxmi Dental modified its IPO object to establish an integrated manufacturing plant (land, building, and machinery) instead of standalone machinery purchases, extending deployment into FY27-FY28.
Why it mattersThe ₹48.10 Cr capex reallocation represents ~16.8% of TTM revenue (₹287 Cr) and will support long-term capacity expansion for clear aligners and dental laboratory products.
Total IPO proceeds: ₹128.17 CrUtilized IPO funds: ₹80.07 Cr (62.47%)Reallocated capex amount: ₹48.10 CrReallocated funds vs TTM Revenue: ~16.8%Revised completion timeline: FY27-FY28
📅 Short termShareholders will vote on the proposed variation; trading window remains closed until 48 hours post-AGM results.
📈 Long termSetting up a dedicated manufacturing facility for dental aligners and lab products is expected to strengthen production scale and margin profile as Bizdent is fully amalgamated.
⚠ Risk flags
- Execution timeline risks associated with land due diligence, regulatory approvals, and construction milestones
- Shareholder approval is required for the object variation
Key Highlights
Reallocated ₹48.10 Cr of unspent IPO proceeds toward land, building infrastructure, and plant equipment
₹26.90 Cr earmarked for land acquisition & facility construction for dental laboratory and aligners
₹21.21 Cr allocated for machineries, IT, and movable assets for deployment across FY27 and FY28
62.47% (₹80.07 Cr) of total IPO proceeds of ₹128.17 Cr already deployed as of August 18, 2026
Allotted 7,911 equity shares under ESOP 2024, expanding share capital to 5,50,29,420 shares
👀 What to Watch
Track shareholder voting approval at the upcoming AGM and monitor updates on definitive agreements for land acquisition following the executed Letter of Intent.
Q1 FY27 PAT Rises 23.8% YoY to ₹10.3 Cr as Revenue Hits Record ₹74.7 Cr
Laxmi Dental released its Q1 FY27 earnings conference call transcript, detailing a record quarterly revenue of ₹74.7 Cr, up 13.9% YoY. Net profit increased 23.8% YoY to ₹10.3 Cr with a 13.8% PAT margin, while EBITDA expanded 20.6% YoY to ₹14.4 Cr (19.2% margin). Growth was propelled by the international lab business (up 37.4% YoY), aligner solutions (up 28.6% YoY), and Kids-e-Dental (up 54.4% YoY). The company has also signed a Letter of Intent (LoI) to acquire land in Palghar, Maharashtra, to transition from leased premises to an owned manufacturing facility.
Confidence: HIGH
What changedLaxmi Dental conducted its Q1 FY27 earnings call, sharing operational updates including US leadership expansion, international lab traction, and plans to acquire manufacturing land in Palghar.
Why it mattersHigh-margin international lab exports and aligner products are driving margin expansion, while moving to an owned facility will provide cost control and capacity scalability.
Q1 FY27 Revenue: ₹74.7 CrQ1 FY27 PAT: ₹10.3 CrEBITDA Margin: 19.2%Gross Margin: 78.6%International Lab Growth (YoY): 37.4%
📅 Short termReflects healthy execution and continuous momentum across core and high-growth dental verticals.
📈 Long termTransition to owned manufacturing facilities, digital workflow adoption, and deeper US market expansion position the company for sustainable long-term scale.
⚠ Risk flags
- Higher other expenses due to freight, provisions, and automation investments
- Potential global tariff/trade barriers affecting international sales
Key Highlights
Q1 FY27 revenue grew 13.9% YoY to ₹74.7 Cr, marking its highest-ever quarterly top-line.
PAT rose 23.8% YoY to ₹10.3 Cr, driven by gross margin expansion to 78.6% (gross profit of ₹58.7 Cr).
International lab business surged 37.4% YoY; aligner segment grew 28.6% YoY (Bizdent up 27.8%, Vedia up 29.3%).
Kids-e-Dental paediatric business reported strong growth of 54.4% YoY.
Executed an LoI to acquire land in Palghar, Maharashtra, to shift operations from leased to owned premises.
👀 What to Watch
Track progress on the land acquisition and facility setup in Palghar, along with international market penetration following the appointment of the new US CEO.
₹6.21 Cr Land Acquisition LOI and Allotment of 59,360 ESOP Shares
Laxmi Dental Limited has approved the execution of a Letter of Intent (LOI) for the acquisition of land in Palghar, Maharashtra, for a total consideration of ₹6.21 crore. The company also allotted 59,360 equity shares to employees under its ESOP 2024 scheme, resulting in a marginal increase in paid-up capital. Additionally, the board noted the surrender/cancellation of 1,636 employee stock options. These moves indicate a focus on infrastructure expansion and employee retention.
Confidence: HIGH
What changedThe company has committed to a ₹6.21 crore land purchase and marginally expanded its equity base through employee stock options.
Why it mattersThe land acquisition suggests a strategic move toward capacity expansion or new facility development, which is a lead indicator for future growth. The ESOP allotment is a routine compensation mechanism but results in minor equity dilution.
Land Acquisition Consideration: ₹6,21,00,000ESOP Shares Allotted: 59,360Post-Allotment Share Count: 5,50,21,509Options Cancelled: 1,636Face Value per Share: ₹2
📅 Short termThe news is likely to be viewed positively as it signals expansionary intent, though the immediate financial impact is limited to the land outflow.
📈 Long termThe acquisition of land is a structural positive that could lead to increased production capacity in the coming years, depending on the development timeline.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk related to the finalization of the land acquisition
- Minor equity dilution from ESOP allotment
Key Highlights
Execution of LOI for land acquisition in Palghar for ₹6,21,00,000
Allotment of 59,360 equity shares of face value ₹2 each under ESOP 2024
Total paid-up equity shares increased from 5,49,62,149 to 5,50,21,509
Cancellation/Forfeiture of 1,636 employee stock options noted
Land acquisition situated in Palghar, Maharashtra
👀 What to Watch
Investors should monitor the transition from the Letter of Intent to a definitive sale deed and the subsequent announcement regarding the intended use (manufacturing vs. logistics) for the Palghar land.
23.8% PAT Growth: Laxmi Dental Reports Record Quarterly Revenue of ₹74.7 Cr in Q1 FY27
Laxmi Dental reported its highest-ever quarterly revenue of ₹74.7 crore for Q1 FY27, a 13.9% YoY increase. Profitability showed strong momentum with PAT rising 23.8% YoY to ₹10.32 crore, while EBITDA margins expanded by 100 bps to 19.2%. Growth was primarily driven by the international dental laboratory segment, which surged 37.4% YoY, and the Aligner Solutions business, which grew 28.6% YoY. The company is strengthening its global footprint by appointing a new CEO for its US operations and establishing three new support facilities in India.
Confidence: HIGH
What changedLaxmi Dental achieved record quarterly revenue and margin expansion, shifting its product mix toward higher-margin international lab services and aligners.
Why it mattersThe strong performance in international markets (37.4% growth) validates the company's export-led growth strategy and its ability to maintain high gross margins (78.6%) despite rising freight costs.
Q1 FY27 Revenue: ₹74.7 CrRevenue vs TTM Revenue: 26.8%PAT (Q1 FY27): ₹10.32 CrEBITDA Margin: 19.2%International Growth: 37.4%Gross Margin: 78.6%
📅 Short termThe stock is likely to react positively to the record revenue and margin expansion, reflecting strong operational execution.
📈 Long termThe company's focus on digital dentistry, AI-led automation, and international expansion positions it well to meet its 20-25% growth guidance over the coming years.
⚠ Risk flags
- Higher freight costs impacting other expenses
- Increased ECL (provisions) noted in the quarter
- Potential US tariff impacts on margins (historical 90 bps risk)
Key Highlights
Highest-ever quarterly revenue of ₹74.7 crore, representing 13.9% YoY growth.
International operations grew by 37.4% YoY, significantly outperforming overall growth.
EBITDA margins improved to 19.2% from 18.2% in Q1 FY26, driven by a better product mix.
Aligner Solutions business maintained momentum with 28.6% YoY growth.
Gross margins reached 78.6%, showing both sequential and year-on-year improvement.
👀 What to Watch
Watch for the execution of the US market strategy under the new CEO and the operational efficiency gains from the three newly established domestic support facilities.
₹6.21 Cr Land Acquisition LOI Signed and 59,360 ESOP Shares Allotted by Laxmi Dental
Laxmi Dental Limited has executed a Letter of Intent (LOI) to acquire land in Palghar, Maharashtra, for a total consideration of ₹6.21 crore, signaling potential future capacity expansion. Simultaneously, the company allotted 59,360 equity shares of ₹2 face value each to employees under its ESOP 2024 scheme. This allotment increases the total paid-up equity share capital from 5,49,62,149 to 5,50,21,509 shares. The board also recorded the surrender of stock options by an employee, Mr. Ansari Mohammed Saad.
Confidence: HIGH
What changedThe company has formally initiated a land acquisition process in Maharashtra and marginally expanded its equity base through employee stock option exercises.
Why it mattersThe land acquisition indicates a physical footprint expansion which is a precursor to capacity growth, while the ESOP allotment reflects the ongoing execution of employee incentive programs.
Land Acquisition Consideration: ₹6,21,00,000ESOP Shares Allotted: 59,360Post-Allotment Total Shares: 5,50,21,509Share Face Value: INR 2
📅 Short termThe news is likely to be viewed neutrally to slightly positively as it confirms expansion intent, though the financial impact of the land purchase is relatively small.
📈 Long termThe acquisition of land provides the structural basis for future manufacturing or R&D expansion, which could drive long-term volume growth if executed well.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk related to the finalization of the land acquisition
- Potential for further equity dilution if more ESOPs are exercised
Key Highlights
Executed Letter of Intent for land acquisition in Palghar for ₹6,21,00,000
Allotted 59,360 equity shares under the Laxmi Dental Stock Option Scheme 2024
Total paid-up share capital increased to 5,50,21,509 equity shares post-allotment
Noted the surrender of employee stock options by Mr. Ansari Mohammed Saad
Land acquisition is situated in Palghar, Maharashtra, for industrial/business use
👀 What to Watch
Investors should monitor the transition from Letter of Intent to final sale deed for the Palghar land and watch for subsequent announcements regarding the specific utilization (manufacturing vs. logistics) of this new site.
₹74.7 Cr Revenue: Laxmi Dental Reports 13.9% YoY Growth and Margin Expansion in Q1FY27
Laxmi Dental achieved its highest-ever quarterly revenue of ₹74.7 Cr in Q1FY27, a 13.9% YoY increase, driven by strong growth in the Dental Laboratory (+23.5%) and Aligner (+28.6%) segments. Profitability improved significantly with PAT rising 23.8% YoY to ₹10.32 Cr, supported by a better product mix that pushed gross margins to 78.6%. International laboratory operations were a standout, growing 37.4% YoY, while the company strengthened its US leadership with a new CEO appointment. However, scanner sales saw a sharp 62% YoY decline to ₹2.2 Cr, which management attributed to minimal contribution during the quarter.
Confidence: HIGH
What changedThe company achieved record quarterly revenue and significant margin expansion while strengthening its international leadership team and domestic support infrastructure.
Why it mattersThe results validate the company's integrated dental model and its ability to scale high-margin laboratory and aligner products internationally, offsetting volatility in equipment sales.
Q1FY27 Revenue: ₹74.7 CrQ1 Revenue vs TTM Revenue: 26.87%Gross Margin: 78.6%International Lab Growth: 37.4%Scanner Sales: ₹2.2 CrUnutilized IPO Funds: ₹64 Cr
📅 Short termThe stock may react positively to the record revenue and margin improvement, though the decline in scanner sales warrants caution regarding equipment demand.
📈 Long termStructural growth remains tied to digital dentistry adoption and international expansion; the company's position as a leading export lab provides a long-term competitive moat.
⚠ Risk flags
- Significant 62% decline in scanner sales
- Rising employee costs due to US expansion
- Exposure to international trade barriers/tariffs
Key Highlights
Highest-ever quarterly revenue of ₹74.7 Cr, representing 13.9% YoY growth compared to Q1FY26.
International laboratory business grew by 37.4% YoY, reflecting strong global market penetration following US FDA registration.
Gross margins improved to 78.6% in Q1FY27 from 73.3% in Q1FY26, driven by a shift toward higher-value product mixes.
Aligner Solutions business maintained momentum with 28.6% YoY growth, contributing ₹23.8 Cr to the top line.
Scanner sales dropped 62% YoY to ₹2.2 Cr, highlighting volatility in equipment-led revenue compared to recurring lab services.
👀 What to Watch
Investors should monitor the execution of the US market strategy under the new leadership and the deployment of ₹64 Cr in unutilized IPO funds for planned automation and capacity expansion.
Laxmi Dental to acquire Palghar land for Rs 6.21 Cr; approves Q1 FY27 results
Laxmi Dental has executed a Letter of Intent to acquire land in Palghar, Maharashtra, for Rs 6.21 Cr to expand manufacturing operations. This investment represents approximately 2.5% of the company's net worth of Rs 247 Cr. The board also approved Q1 FY27 financial results and allotted 59,360 equity shares under its ESOP 2024 scheme, resulting in a marginal 0.1% equity dilution. Five subsidiaries reported a combined revenue of Rs 15.7 Cr and a net profit of Rs 1.75 Cr for the quarter ended June 30, 2026.
Confidence: HIGH
What changedThe company has initiated a land acquisition for business expansion and slightly increased its share capital through employee stock options.
Why it mattersThe land acquisition signals the start of planned capacity expansion to meet rising demand, though the current investment is small relative to the company's total market cap of Rs 1160 Cr.
Land Consideration: Rs 6.21 CrLand vs Net Worth: ~2.5%ESOP Allotment: 59,360 sharesEquity Dilution: ~0.1%Subsidiary Revenue (Q1): Rs 15.7 CrAdvance Paid: Rs 51 Lakhs
📅 Short termThe market is likely to react neutrally as the land acquisition is small and the ESOP dilution is negligible; focus will remain on the full Q1 FY27 earnings performance.
📈 Long termThe expansion into a new factory at Palghar aligns with the company's strategy to scale its branded portfolio and international penetration, though execution remains key.
⚠ Risk flags
- Execution risk for the new factory construction
- Potential margin pressure from international trade barriers as noted in historical filings
Key Highlights
Acquisition of land in Palghar for a total consideration of Rs 6.21 Cr for factory construction
Advance payment of Rs 51 Lakhs already executed as part of the Letter of Intent
Allotment of 59,360 equity shares at an exercise price of Rs 2 per share under ESOP 2024
Five subsidiaries reported combined revenue of Rs 15.7 Cr (Rs 157.01 million) for Q1 FY27
Total paid-up equity share capital increased to 5,50,21,509 shares post-allotment
👀 What to Watch
Monitor the construction timeline for the Palghar factory and the deployment of the remaining Rs 64 Cr unutilized IPO funds for future capacity expansion.
Laxmi Dental Q4 FY26 Revenue Up 22% YoY to ₹74 Cr; Reports Highest Ever Quarterly Performance
Laxmi Dental Limited delivered its strongest quarterly performance in Q4 FY26, with revenue growing 22% YoY to ₹74 crores and PAT reaching ₹10.1 crores. The growth was primarily driven by a 40.9% YoY surge in the international lab business and a 16.3% rise in domestic operations. Despite external headwinds like US tariffs and global freight volatility, the company improved its EBITDA margin to 18.3% and maintained a debt-free balance sheet with ₹99 crores in cash and investments. The management is aggressively pushing digital dentistry, with digital penetration in the domestic lab business now at 80%.
Key Highlights
Achieved highest-ever quarterly revenue of ₹74 crores, up 21.9% YoY, and annual revenue of ₹277.9 crores.
International lab business grew by 40.9% YoY, while the domestic lab segment grew by 16.3%.
EBITDA margins expanded to 18.3% in Q4 FY26 from 15.7% in the same period last year.
Company remains debt-free with a strong liquidity position of ₹99 crores in cash and bank balances.
Digital penetration in the domestic lab business reached 80%, with a medium-term target of 90%.
👀 What to Watch
Investors should monitor the company's ability to maintain high margins while scaling the international business and the adoption rate of its new AI-driven platform, iScope 360. The debt-free status and strong cash position provide significant cushion for future expansion.
Laxmi Dental Q4 FY26: Revenue Up 21.9% to ₹74 Cr, PAT Surges 136% YoY
Laxmi Dental Limited reported its highest-ever quarterly revenue of INR 739.5 Mn in Q4 FY26, representing a 21.9% YoY growth. The company achieved a significant PAT jump of 136.1% YoY to INR 100.9 Mn for the quarter, despite headwinds like US tariffs and geopolitical uncertainties. While full-year FY26 PAT declined 9.2% to INR 289.2 Mn, this was due to a non-comparable high base in FY25 which included a one-time property sale gain of INR 70.3 Mn. The core Dental Laboratory business remains strong with 27% YoY growth in Q4.
Key Highlights
Q4 FY26 Revenue reached a record INR 739.5 Mn, up 21.9% YoY and 12% QoQ.
EBITDA margins for Q4 improved to 18.3% from 15.7% YoY, despite a 74 bps impact from US tariffs.
Core Dental Laboratory business grew 27% YoY in Q4, driven by domestic recovery and international revenue.
Scanner sales, acting as a strategic growth enabler, surged 282% YoY in Q4 to INR 82 Mn.
Full-year FY26 revenue stood at INR 2,778.6 Mn, a 16.2% increase over the previous fiscal year.
👀 What to Watch
Investors should view the strong quarterly recovery and record revenue as a sign of robust demand in digital dentistry and aligner solutions. Monitor the impact of US tariffs and geopolitical freight costs on margins in the coming quarters.
Laxmi Dental Q4FY26 Revenue Rises 21.9% YoY to ₹74 Cr; Highest-Ever Quarterly Performance
Laxmi Dental reported its highest-ever quarterly revenue of ₹74.0 Cr in Q4FY26, marking a 21.9% YoY growth. Despite geopolitical challenges and higher US tariffs, the company maintained healthy EBITDA margins of 18.3% and PAT margins of 13.6% for the quarter. Full-year FY26 revenue reached ₹278 Cr, supported by strong recovery in domestic business and record international operations. The company is successfully transitioning to digital dentistry with approximately 80% digital penetration in its Indian operations.
Key Highlights
Q4FY26 revenue grew 21.9% YoY to ₹74.0 Cr, driven by a 27% growth in the Dental Laboratory segment.
Full-year FY26 revenue stood at ₹278 Cr with a consolidated PAT of ₹28.9 Cr.
Digital penetration in the Indian dental business reached ~80%, highlighting a shift towards high-tech dentistry.
Scanner sales surged 282% YoY in Q4 to ₹8.2 Cr, acting as a strategic enabler for future lab and aligner growth.
EBITDA margins for Q4 improved to 18.3% from 15.7% YoY, despite a 74 bps impact from US tariffs.
👀 What to Watch
Investors should monitor the company's ability to scale its Aligner business and manage international tariff risks. The strong digital adoption and record quarterly performance suggest a positive growth trajectory in the specialized dental healthcare space.
Laxmi Dental Q4 FY26 PAT Surges 136% YoY to ₹10.1 Cr; Revenue Hits Record High
Laxmi Dental reported a robust Q4 FY26 performance with revenue growing 21.9% YoY to ₹739.5 Mn, marking its highest-ever quarterly revenue. Quarterly PAT jumped 136.1% YoY to ₹100.9 Mn, driven by strong growth in the Dental Laboratory segment (up 27% YoY) and improved EBITDA margins of 18.3%. While full-year FY26 PAT declined 9.2% to ₹289.2 Mn, this was primarily due to a high base in FY25 (which included a ₹70.3 Mn property sale gain) and a one-time ₹57.8 Mn labor code expense in FY26. The company's digital penetration in India has reached a significant 80%.
Key Highlights
Q4 FY26 Revenue grew 21.9% YoY to ₹739.5 Mn, driven by domestic recovery and international operations.
EBITDA for Q4 FY26 rose 41.8% YoY to ₹135.0 Mn with margins expanding to 18.3%.
Dental Laboratory business achieved its highest-ever quarterly performance with 27% YoY growth.
Aligner Solutions segment reported Q4 revenue of ₹180 Mn, with Bizdent growing 11% YoY.
FY26 performance was impacted by 72 bps US tariff impact and ₹52.6 Mn in ESOP expenses.
👀 What to Watch
The strong Q4 exit and record revenue suggest robust operational momentum and successful digital adoption. Investors should focus on the growth of the Aligner Solutions business and the company's ability to manage international tariff pressures.
Laxmi Dental FY26 Revenue Grows 22% to ₹2,060M; Q4 Net Profit Jumps 63% YoY
Laxmi Dental reported a strong operational performance for FY26, with annual revenue from operations rising 21.8% to ₹2,060.37 million. Although the reported net profit for the full year decreased to ₹193.37 million from ₹257.75 million due to a high base involving exceptional items in the previous year, the core Profit Before Tax (before exceptional items) surged 50.8% to ₹261.26 million. The fourth quarter showed significant momentum, with net profit rising 62.8% YoY to ₹67.98 million, supported by robust sales growth and improved operational margins.
Key Highlights
Annual Revenue from Operations increased 21.8% YoY to ₹2,060.37 million in FY26.
Profit Before Exceptional Items and Tax for the full year grew by 50.8% to ₹261.26 million.
Q4 FY26 Net Profit stood at ₹67.98 million, a significant 62.8% increase over ₹41.75 million in Q4 FY25.
Total Income for the quarter ended March 31, 2026, reached ₹577.26 million vs ₹448.63 million YoY.
Full-year Basic EPS stood at ₹3.52, reflecting the underlying operational strength despite the absence of prior-year exceptional gains.
👀 What to Watch
Investors should look past the headline net profit decline, which was caused by one-off gains in the previous year, and focus on the 50% growth in core operating profit. The strong Q4 performance and consistent revenue growth suggest a healthy outlook for the company's dental solutions business.
Laxmi Dental Approves Merger with Bizdent Devices and Cancels 32,538 ESOP Options
Laxmi Dental Limited has approved the amalgamation of its wholly-owned subsidiary, Bizdent Devices Private Limited, into itself to simplify group structure and achieve operational synergies. Bizdent specializes in aligners, sleep apnea devices, and sports guards, and the merger is expected to reduce administrative costs and improve financial strength. As Bizdent is a 100% subsidiary, no new shares will be issued, and there will be no change in the shareholding pattern. Additionally, the company reported the cancellation of 32,538 ESOP options and several key management and auditor appointments.
Key Highlights
Approved Scheme of Amalgamation with wholly-owned subsidiary Bizdent Devices Private Limited
Forfeiture and cancellation of 32,538 ESOP options reported
No change in shareholding pattern as the transferor company is a 100% subsidiary
Appointment of Bathiya Advisors LLP as Internal Auditors for FY 2026-27
Redesignation of Mr. Mitesh Kariya as Chief Operating Officer – Illusion Dental
👀 What to Watch
The merger is a positive move for corporate simplification and cost rationalization. Investors should view this as a structural improvement that could lead to better operational margins in the long term.
Laxmi Dental Approves Merger of Wholly Owned Subsidiary Bizdent Devices
Laxmi Dental Limited has approved the Scheme of Amalgamation of its wholly-owned subsidiary, Bizdent Devices Private Limited, into itself to simplify group structure and achieve operational synergies. Bizdent Devices specializes in aligners, sleep apnea devices, and sports guards, and its integration is expected to reduce administrative and compliance costs. Since the subsidiary is 100% owned, no new shares will be issued, and there will be no change in the parent company's shareholding pattern. The board also appointed new internal auditors for FY 2026-27 and updated several corporate governance policies.
Key Highlights
Approved merger of 100% subsidiary Bizdent Devices Private Limited with Laxmi Dental Limited.
No equity dilution as all shares of the transferor company will be cancelled upon amalgamation.
Appointment of Bathiya Advisors LLP as Internal Auditors for the financial year 2026-27.
Re-appointment of M/s. Abhay Subhash & Associates as Tax Auditors for FY 2025-26.
Redesignation of Mr. Mitesh Kariya as Chief Operating Officer – Illusion Dental.
👀 What to Watch
Investors should view the merger as a positive move toward corporate simplification and cost rationalization. Monitor the timeline for regulatory approvals from the Regional Director and Stock Exchanges to ensure smooth integration.
Laxmi Dental to Merge Subsidiary Bizdent Devices; Appoints New Internal Auditors
Laxmi Dental Limited has approved the merger of its wholly-owned subsidiary, Bizdent Devices Private Limited, into itself to streamline operations and reduce administrative costs. Bizdent Devices specializes in aligners and sleep apnea devices, and its consolidation is expected to create a stronger financial base and eliminate inter-company transactions. As Bizdent is a 100% subsidiary, no new shares will be issued, leaving the parent company's shareholding pattern unchanged. Additionally, the board appointed Bathiya Advisors LLP as Internal Auditors for FY 2026-27 and re-appointed Tax Auditors for FY 2025-26.
Key Highlights
Board approved the Scheme of Amalgamation of Bizdent Devices Private Limited (WOS) with Laxmi Dental Limited.
The merger will result in the cancellation of the subsidiary's entire share capital with no new equity issuance.
Bathiya Advisors LLP appointed as Internal Auditors for FY 2026-27, effective April 1, 2026.
Abhay Subhash & Associates re-appointed as Tax Auditors for the financial year 2025-26.
Mr. Mitesh Kariya redesignated as Chief Operating Officer – Illusion Dental to strengthen leadership.
👀 What to Watch
Investors should view the internal merger as a positive move for operational efficiency and cost rationalization. Monitor the timeline for regulatory approvals from the Regional Director and Stock Exchanges to confirm the completion of the amalgamation.
Laxmi Dental Board Approves Merger of Wholly Owned Subsidiary Bizdent Devices
Laxmi Dental Limited has approved the Scheme of Amalgamation for its wholly-owned subsidiary, Bizdent Devices Private Limited, to merge into the parent company. The merger is designed to simplify the corporate structure, eliminate inter-company transactions, and reduce administrative and compliance costs. As Bizdent is a 100% subsidiary, no new shares will be issued, and the shareholding pattern of Laxmi Dental will remain unchanged. The board also approved the appointment of new internal auditors for FY 2026-27 and updated several corporate governance policies.
Key Highlights
Merger of wholly-owned subsidiary Bizdent Devices Private Limited into Laxmi Dental Limited approved by the Board.
No new shares to be issued; the entire paid-up share capital of the subsidiary will be cancelled and extinguished.
Bizdent Devices specializes in manufacturing aligners, sleep apnoea devices, and sports guards.
M/s. Bathiya Advisors LLP appointed as Internal Auditors for the financial year 2026-27.
Mr. Mitesh Kariya redesignated as Chief Operating Officer – Illusion Dental effective March 26, 2026.
👀 What to Watch
Investors should view this as a positive move toward corporate simplification and operational efficiency. Monitor the company's upcoming quarterly results for any immediate impact on administrative cost reductions.
Laxmi Dental Q3FY26 Revenue Grows 7.1% to ₹66 Cr; US Tariffs Reduced to 25%
Laxmi Dental reported a 7.1% YoY revenue growth to ₹66 crores for Q3FY26, driven by a 25% surge in international lab business. Profitability was temporarily impacted by a 150 bps hit from US tariffs and a one-time exceptional item of ₹5.8 crores related to the new labor code. However, the recent India-US trade deal has halved tariffs from 50% to 25%, which is expected to significantly improve margins in the coming quarters. The company remains debt-free and reported strong recovery trends in January 2026 across all business segments.
Key Highlights
Revenue from operations increased 7.1% YoY to ₹66 crores, with 9MFY26 revenue reaching ₹203.9 crores.
US import tariffs reduced from 50% to 25% in February 2026, easing pressure on the international segment.
Scanner sales grew by 46% YoY to ₹6.4 crores, supporting the company's digital dentistry mission.
Recorded a one-time exceptional expense of ₹5.8 crores due to new labor code and accounting standard requirements.
Company is now debt-free, leading to a sharp decline in finance costs to ₹0.3 crore from ₹1.5 crore YoY.
👀 What to Watch
Investors should focus on the anticipated margin expansion in Q4FY26 as the lower US tariffs and the absence of one-time labor costs take effect. The strong growth in high-tech segments like scanners and international labs makes it a key player to watch in the dental healthcare space.
Laxmi Dental Q3 Revenue Up 7.1% YoY to ₹660 Mn; PAT Drops 59% on Exceptional Item
Laxmi Dental reported a 7.1% YoY revenue growth in Q3FY26, reaching ₹660.4 million, driven by strong international lab business growth of 25.5%. However, PAT declined significantly by 59.3% YoY to ₹19.6 million, primarily due to a one-time exceptional provision of ₹57.8 million for gratuity liabilities under new labour codes. EBITDA margins compressed to 10.6% from 15.6% a year ago, impacted by higher US tariffs (150 bps) and ESOP expenses. Management remains optimistic about Q4 recovery in the domestic market and normalization of pricing pressures in the aligner segment.
Key Highlights
Revenue grew 7.1% YoY to ₹660.4 Mn in Q3FY26; 9M FY26 revenue up 14.3% to ₹2,039 Mn.
PAT fell 59.3% YoY to ₹19.6 Mn, impacted by a ₹57.8 Mn exceptional item for labour code compliance.
International dental lab business showed robust growth of 25.5% YoY, offsetting soft domestic performance.
EBITDA margins stood at 10.6%, affected by 150 bps impact from US tariffs and ₹16.14 Mn ESOP expenses.
Gross profit margins remained steady at 69.5% with sequential improvement due to lower low-margin scanner sales.
👀 What to Watch
Investors should monitor the recovery in domestic lab and aligner segments in Q4, as management indicates positive trends starting January 2026. While one-time costs hit the bottom line, the strong international growth and strategic positioning in digital dentistry remain key long-term drivers.
